Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 1–50 of 34655
On July 8, 2026, Nathaniel Fick resigned from his role as a Class III director of the Board, effective July 8, 2026, to accept an appointment as preferred stock director of the Board.
On July 9, 2026, the Board appointed Haiyan Song, age 60, to the Board.
Nathaniel Fick will succeed Mr. Nixon as a preferred stock director of the Board, effective July 8, 2026.
On July 8, 2026, Greg Nixon resigned from his role as a preferred stock director of the Board of Directors (the “Board”) of Eos Energy Enterprises, Inc. (the “Company”), effective July 8, 2026, to devote more time to other business ventures.
the directors of Merger Sub immediately prior to the Effective Time, Joseph Bernardello, Peter Limeri and Taylor Curtis, became the directors of the Surviving Corporation.
the directors of Merger Sub immediately prior to the Effective Time, Joseph Bernardello, Peter Limeri and Taylor Curtis, became the directors of the Surviving Corporation.
the directors of Merger Sub immediately prior to the Effective Time, Joseph Bernardello, Peter Limeri and Taylor Curtis, became the directors of the Surviving Corporation.
On July 7, 2026, Daniel R. Kozlowski notified the Board of Directors (the “ Board ”) of the Registrant of his resignation from the Board, effective immediately.
On July 2, 2026, Matt Link notified FibroBiologics, Inc. (the “Company”) that he was resigning from the Board of Directors (the “Board”), effective as of July 2, 2026.
On July 8, 2026, the Board appointed Kathleen Rubins, Ph.D. as a Class III director of the Board, effective July 8, 2026, to serve until the expiration of her term at the 2029 annual meeting of stockholders.
On July 6, 2026, the Board appointed Ms. Kristina Campbell (“Ms. Campbell”) to serve as a member of the Board, effective immediately.
each of the directors of the Company (Patrick J. McEnany; Richard J. Daly; Daniel J. Curran, M.D.; Donald A. Denkhaus; Molly Harper; Tamar Thompson; and David S. Tierney, M.D.) has indicated their intention to resign as a member of the board of directors of the Company and any committee thereof, as applicable, conditioned upon and effective as of the effective time of the Merger.
each of the directors of the Company (Patrick J. McEnany; Richard J. Daly; Daniel J. Curran, M.D.; Donald A. Denkhaus; Molly Harper; Tamar Thompson; and David S. Tierney, M.D.) has indicated their intention to resign as a member of the board of directors of the Company and any committee thereof, as applicable, conditioned upon and effective as of the effective time of the Merger.
each of the directors of the Company (Patrick J. McEnany; Richard J. Daly; Daniel J. Curran, M.D.; Donald A. Denkhaus; Molly Harper; Tamar Thompson; and David S. Tierney, M.D.) has indicated their intention to resign as a member of the board of directors of the Company and any committee thereof, as applicable, conditioned upon and effective as of the effective time of the Merger.
each of the directors of the Company (Patrick J. McEnany; Richard J. Daly; Daniel J. Curran, M.D.; Donald A. Denkhaus; Molly Harper; Tamar Thompson; and David S. Tierney, M.D.) has indicated their intention to resign as a member of the board of directors of the Company and any committee thereof, as applicable, conditioned upon and effective as of the effective time of the Merger.
each of the directors of the Company (Patrick J. McEnany; Richard J. Daly; Daniel J. Curran, M.D.; Donald A. Denkhaus; Molly Harper; Tamar Thompson; and David S. Tierney, M.D.) has indicated their intention to resign as a member of the board of directors of the Company and any committee thereof, as applicable, conditioned upon and effective as of the effective time of the Merger.
each of the directors of the Company (Patrick J. McEnany; Richard J. Daly; Daniel J. Curran, M.D.; Donald A. Denkhaus; Molly Harper; Tamar Thompson; and David S. Tierney, M.D.) has indicated their intention to resign as a member of the board of directors of the Company and any committee thereof, as applicable, conditioned upon and effective as of the effective time of the Merger.
each of the directors of the Company (Patrick J. McEnany; Richard J. Daly; Daniel J. Curran, M.D.; Donald A. Denkhaus; Molly Harper; Tamar Thompson; and David S. Tierney, M.D.) has indicated their intention to resign as a member of the board of directors of the Company and any committee thereof, as applicable, conditioned upon and effective as of the effective time of the Merger.
each of Robert Neal, Mark Smith and Eduardo Munemori ceased to be a director of RAAQ
each of Robert Neal, Mark Smith and Eduardo Munemori ceased to be a director of RAAQ
each of Robert Neal, Mark Smith and Eduardo Munemori ceased to be a director of RAAQ
the following individuals also ceased to be directors: Danny H. Salinas, Robert G. Sharp, Louis Zurita and Dr. Mukesh Prasad.
the following individuals also ceased to be directors: Danny H. Salinas, Robert G. Sharp, Louis Zurita and Dr. Mukesh Prasad.
the following individuals also ceased to be directors: Danny H. Salinas, Robert G. Sharp, Louis Zurita and Dr. Mukesh Prasad.
the following individuals also ceased to be directors: Danny H. Salinas, Robert G. Sharp, Louis Zurita and Dr. Mukesh Prasad.
On July 1, 2026, Karen Ferrante, M.D. provided notice to the board of directors (the “Board”) of MacroGenics, Inc. (the “Company”) of her decision to resign from the Board, effective September 1, 2026.
On July 6, 2026, the Board of Trustees (the “Board”) of Power REIT (the “Trust”) appointed Brent Morrison to serve as an independent trustee of the Trust, effective immediately.
Effective July 3, 2026, the Board of Directors elected Radek Chovanec to serve as a Director of the Company.
Effective July 7, 2026, John Williams, Jr., a member of the Board of Directors (the “Board”) of Old Second Bancorp, Inc. (the “Company”), resigned from the Board.
Effective July 1, 2026, Mr. Matthew Toboroff was appointed to our Board of Directors to fill a vacancy created by the passing of Thom Kidrin.
On July 3, 2026, the Board of Directors (the “Board”) of Aura Biosciences, Inc. (the “Company”) increased the size of the Board from six to seven directors and unanimously appointed Jeremy Bender, Ph.D., M.B.A., as a Class II director, effective July 7, 2026 (the “Effective Date”), to fill the newly created vacancy.
On July 1, 2026, the Board of Directors of Internet Sciences, Inc. (the "Company") appointed Keith R. Wyche to serve as a member of the Board of Directors of the Company, effective July 1, 2026.
appointed the following directors to fill the vacancies created by Mr. van den Heuvel’s resignation and the increase in the size of the Board: Brian McConville Ana Rita Coelho Mariana Mourawad
appointed the following directors to fill the vacancies created by Mr. van den Heuvel’s resignation and the increase in the size of the Board: Brian McConville Ana Rita Coelho Mariana Mourawad
appointed the following directors to fill the vacancies created by Mr. van den Heuvel’s resignation and the increase in the size of the Board: Brian McConville Ana Rita Coelho Mariana Mourawad
Doug Wall 58 Director
Timothy Stebbing 46 Director
Michael Galloro 51 Director
Duncan Moir 41 Director
Sarosh Mistry 56 Director
Stephen Ilott 58 Director
When the election of Dr. Ackermann and Messrs. Brettschneider, Bouhara and Waugh as directors of the Company became effective on July 6, 2026, each of them entered into an indemnity agreement with the Company.
When the election of Dr. Ackermann and Messrs. Brettschneider, Bouhara and Waugh as directors of the Company became effective on July 6, 2026, each of them entered into an indemnity agreement with the Company.
When the election of Dr. Ackermann and Messrs. Brettschneider, Bouhara and Waugh as directors of the Company became effective on July 6, 2026, each of them entered into an indemnity agreement with the Company.
When the election of Dr. Ackermann and Messrs. Brettschneider, Bouhara and Waugh as directors of the Company became effective on July 6, 2026, each of them entered into an indemnity agreement with the Company.
Mr. Casale was also concurrently appointed to the Board as a Class III director, to serve until the Company’s 2029 annual meeting of stockholders.
On June 30, 2026, the Board of Directors (the “Board”) of the Company appointed Mr. Manuel Benito Miranda as a Class II director to fill a vacancy in that Board Class following an increase in the size of the Board from eight (8) to nine (9) directors.
on July 2, 2026, the Board appointed Thurman Justice, Lori Goltermann and Safwan Shabab as a directors of the Company.
on July 2, 2026, the Board appointed Thurman Justice, Lori Goltermann and Safwan Shabab as a directors of the Company.
on July 2, 2026, the Board appointed Thurman Justice, Lori Goltermann and Safwan Shabab as a directors of the Company.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.